Clinical Trials Browser

Phase 2 × Neoplasms × Clear all

NCT04452955 2026-04-22

A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors

Phase 2 Active not recruiting

Neoplasms

NCT07002034 2026-04-22

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

Phase 2 Recruiting

Adjustment Disorders, Amyotrophic Lateral Sclerosis, Anxiety Disorders, Depression, Multiple Sclerosis, Neoplasms, Idiopathic Pulmonary Fibrosis

NCT07169851 2026-04-22

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

Phase 2 Recruiting

Nausea, Neoplasms, Vomiting, Drug-Related Side Effects and Adverse Reactions

NCT07521852 2026-04-22

A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT04095208 2026-04-21

CONGRATS

Phase 2 Completed

Tertiary Lymphoid Structures, Neoplasm Metastasis, Neoplasms, Sarcoma

NCT06623656 2026-04-21

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Phase 2 Recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT07542158 2026-04-21

Ultralow Dose PET Imaging of 18F-FDOPA

Phase 2 Enrolling by invitation

Glioma, Neoplasms, Parkinsonian Disorders

NCT00092222 2026-04-20

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

Phase 2 Active not recruiting

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Lymphadenopathy, Lymphoproliferative Disorders, Neoplasms, HIV Infections

NCT03441113 2026-04-20

Extended Access of Momelotinib in Adults With Myelofibrosis

Phase 2 Active not recruiting

Neoplasms, Primary Myelofibrosis

NCT05796375 2026-04-20

ReplaceCysto

Phase 2 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT06413706 2026-04-20

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

Phase 2 Active not recruiting

Brain Neoplasms, Glioma, Neoplasms, Spinal Cord Neoplasms

NCT07205731 2026-04-20

SAFE ESO

Phase 2 Recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Neoplasms

NCT03967223 2026-04-17

IGNYTE-ESO

Phase 2 Active not recruiting

Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT07252739 2026-04-17

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Phase 2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT05064280 2026-04-16

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

Phase 2 Recruiting

Brain Neoplasms, Neoplasms

NCT06510699 2026-04-16

PRAGMATIC

Phase 2 Recruiting

Other hematologic neoplasm

Communicable Diseases, Infections, Mycoses, Neoplasms, Hematologic Neoplasms

NCT06801041 2026-04-16

TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

Phase 2 Recruiting

Anxiety Disorders, Depression, Neoplasms

NCT07533227 2026-04-16

FMT-CACH

Phase 2 Not yet recruiting

Cachexia, Neoplasms

NCT04486378 2026-04-15

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT05065801 2026-04-15

GABRINOX2

Phase 2 Recruiting

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT06458036 2026-04-15

RAISE

Phase 2 Recruiting

Neoplasms, Thyroid Neoplasms

NCT06502977 2026-04-15

DeLLphi-307

Phase 2 Active not recruiting

32 enrolled 9 charts

Neoplasms, Neuroendocrine Tumors

NCT07216443 2026-04-15

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 2 Recruiting

MyeloidOther hematologic neoplasmOther neoplasm

Acute Disease, Bone Marrow Diseases, Disease, Graft vs Host Disease, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Precancerous Conditions, Preleukemia, Syndrome, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Disease Attributes

NCT05797246 2026-04-14

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

Phase 2 Active not recruiting

DNA Virus Infections, Infections, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Pathologic Processes, Recurrence, Respiratory Tract Diseases, Respiratory Tract Infections, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Disease Attributes, Papillomavirus Infections

NCT06906341 2026-04-14

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Phase 2 Recruiting

Fallopian Tube Diseases, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

NCT06915116 2026-04-14

Acupuncture for People Experiencing Period Loss Due to Chemotherapy

Phase 2 Recruiting

Menstruation Disturbances, Neoplasms

NCT02101775 2026-04-13

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Active not recruiting

124 enrolled 17 charts

Brenner Tumor, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT02864992 2026-04-13

VISION

Phase 2 Active not recruiting

337 enrolled 13 charts 4 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04337580 2026-04-13

FASN

Phase 2 Recruiting

Neoplasms, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT05257590 2026-04-13

CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT05283720 2026-04-13

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05879146 2026-04-13

Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study

Phase 2 Recruiting

Neoplasms

NCT06319378 2026-04-13

CAPSI

Phase 2 Recruiting

Neoplasms

NCT06979596 2026-04-13

OMAHA-015

Phase 2 Recruiting

Neoplasms

NCT07149207 2026-04-13

Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors

Phase 2 Recruiting

Margins of Excision, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms

NCT07209111 2026-04-13

KANDLELIT-014

Phase 2 Recruiting

Neoplasms

NCT07387471 2026-04-13

Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Phase 2 Recruiting

Waldenstrom Macroglobulinemia, Neoplasms, Lymphoma, B-Cell, Marginal Zone

NCT04847466 2026-04-08

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

Phase 2 Active not recruiting

Neoplasms

NCT05852717 2026-04-08

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Phase 2 Recruiting

Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05993299 2026-04-08

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Phase 2 Active not recruiting

7 enrolled 15 charts

Neoplasms

NCT06703346 2026-04-08

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Phase 2 Active not recruiting

Neoplasms

NCT07284589 2026-04-08

Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake

Phase 2 Recruiting

Neoplasms

NCT02626481 2026-04-07

IFM2014-04

Phase 2 Completed

Multiple Myeloma, Neoplasms

NCT06108232 2026-04-07

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

Phase 2 Active not recruiting

Lymphoma, Follicular, Neoplasms

NCT06593522 2026-04-07

A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

Phase 2 Recruiting

Neoplasms

NCT07516210 2026-04-07

ART-Hypo

Phase 2 Not yet recruiting

GastrointestinalGenitourinaryGynecologic

Uterine Cervical Neoplasms, Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Endometrial Neoplasms

NCT03467867 2026-04-06

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoproliferative Disorders, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06152523 2026-04-06

MONAMI

Phase 2 Withdrawn

Neoplasms

NCT07024784 2026-04-06

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Phase 2 Recruiting

Fallopian Tube Neoplasms, Neoplasms

NCT03505320 2026-04-03

ILUSTRO

Phase 2 Active not recruiting

Gastrointestinal

Neoplasms, Stomach Neoplasms